<DOC>
	<DOCNO>NCT01658826</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy `` AIC316 ( pritelivir ) '' 100 mg daily compare valacyclovir 500 mg daily prevention HSV-2 genital shedding .</brief_summary>
	<brief_title>Safety Efficacy Comparator Trial New Drug Against Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Adult , immunocompetent men woman good health ethnic group Seropositive Herpes Simplex Virus Type 2 ( HSV2 ) History recurrent episode ( &gt; =4 &lt; =9 ) genital herpes least 12 month Present episode genital herpes time randomization Clinically relevant acute chronic infection ( exclude HSV2 ) Known intolerance valacyclovir , acyclovir , component formulation Documented HSV resistance acyclovir , valacyclovir , famciclovir penciclovir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AIC316</keyword>
	<keyword>Viral shed</keyword>
</DOC>